Emiltatug Ledadotin (Emi-Le; XMT-1660) (GlobeNewswire) - Nov 14, 2025 - "As of October 1, 2025, Mersana has enrolled a substantially greater number of ACC-1 patients in these backfill cohorts than was presented at ASCO. The data from ACC-1 patients enrolled in this trial continues to mature as Mersana enrolls additional patients and patients remain on treatment for longer periods. Mersana has continued to be encouraged by the responses of the patients in these backfill cohorts....Emi-Le continues to be generally well-tolerated, and its observed safety profile remains consistent with previously disclosed data."
Enrollment status • P1 data • Adenoid Cystic Carcinoma
|